FOLFOXIRI Plus Bevacizumab in Unresectable Metastatic Colorectal Cancer

This systematic review and pooled analysis assesses the efficacy of FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer.

http://ift.tt/2rZ37KP